Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-302 with CapOx-based regimens in metastatic esophagogastric cancer
NL-OMON58677Phase 2Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of MT-302, capecitabine and oxaliplatin in Esophagogastric Cancer, sponsored by Amsterdam University Medical Center. Primary endpoint: Primary endpoint(s). Started Aug 2025; status: recruiting.
02
Drugs
MT-302capecitabineoxaliplatin
03
Conditions
Esophagogastric Cancer
Beyond the preview
Go deeper on NL-OMON58677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58677.